Abstract: A method for increasing the expression of SIRT1 mRNA and/or decreasing the expression of SOCS3 mRNA, and especially for regulating blood glucose levels in a subject in need thereof is provided. The method comprises administering to the subject an effective amount of an active component selected from the group consisting of a compound of formula (I), a pharmaceutically acceptable salt of the compound of formula (I), and combinations thereof: wherein X is H or C1-C3 alkyl; one of Y and Z is and the other one is H, OH or wherein when Y is Z is R1 to R13 are independently H or OH, and wherein, R1 to R3 are not simultaneously H; R8 and R9 are not simultaneously H.

Abstract: The present invention is to provide a two-stage sterilization process for treating heat-resistant spores in a great burdock extract drink, which comprises the steps of sealing dried great burdock and water in a double-kettle pressure cooker; heating liquid mixture of great burdock and water to a first temperature range lower than or equal to 100° C. for at least a first duration during a first-stage sterilization; opening lid of the cooker and filtering out great burdock residue so that all that remains in the cooker is great burdock extract; resealing the cooker and heating the great burdock extract to a second temperature range higher than or equal to 120° C. for at least a second duration during a second-stage sterilization, and the pressure in the cooker during the second-stage sterilization is higher than that during the first-stage sterilization; so as to obtain the extract drink free of common bacteria and heat-resistant spores.

Abstract: A method for increasing the expression of SIRT1 mRNA and/or decreasing the expression of SOCS3 mRNA, and especially for regulating blood glucose levels in a subject in need thereof is provided. The method comprises administering to the subject an effective amount of an active component selected from the group consisting of a compound of formula (I), a pharmaceutically acceptable salt of the compound of formula (I), and combinations thereof: wherein X is H or C1-C3 alkyl; one of Y and Z is and the other one is H, OH or wherein when Y is Z is R1 to R13 are independently H or OH, and wherein, R1 to R3 are not simultaneously H; R8 and R9 are not simultaneously H.

Abstract: A method for increasing the expression of SIRT1 mRNA and/or decreasing the expression of SOCS3 mRNA, and especially for regulating blood glucose levels in a subject in need thereof is provided. The method comprises administering to the subject an effective amount of an active component selected from the group consisting of a compound of formula (I), a pharmaceutically acceptable salt of the compound of formula (I), and combinations thereof: wherein X is H or C1-C3 alkyl; one of Y and Z is and the other one is H, OH or wherein when Y is Z is R1 to R13 are independently H or OH, and wherein, R1 to R3 are not simultaneously H; R8 and R9 are not simultaneously H.

Abstract: A method for increasing the expression of SIRT1 mRNA and/or decreasing the expression of SOCS3 mRNA, and especially for regulating blood glucose levels in a subject in need thereof is provided. The method comprises administering to the subject an effective amount of an active component selected from the group consisting of a compound of formula (I), a pharmaceutically acceptable salt of the compound of formula (I), and combinations thereof: wherein X is H or C1-C3 alkyl; one of Y and Z is and the other one is H, OH or wherein when Y is Z is R1 to R13 are independently H or OH, and wherein, R1 to R3 are not simultaneously H; R8 and R9 are not simultaneously H.

Abstract: A manufacturing method of separating and purifying neoagarooligosaccharides having degrees of polymerization of 2-22 includes the steps of adding crude enzyme solutions with agarases produced by Pseudomonas vesicularis MA103 and Aeromonas salmonicida MAEF108, respectively, into an agar polysaccharide extract solution, and obtaining a neoagarooligosaccharides solution after a hydrolysis on the algal polysaccharide (such as agar) is performed; performing a separation to the neoagarooligosaccharides solution by a ultrafiltration (UF) system to obtain a neoagarooligosaccharide eluent; performing a separation to the neoagarooligosaccharide eluent by a semi-preparative high-performance liquid chromatography system equipped with a molecule size exclusion chromatography function to obtain the neoagarooligosaccharides having the degrees of polymerization from 2 to 22; and using a fraction collector to collect the neoagarooligosaccharides, and obtaining purified single neoagarooligosaccharide products with different mo

Abstract: A particle embedded with chemical substances, especially with physiological activity substances, is disclosed. The particle has (a) the embedded substances, embedded in base materials and ranged from about 0.1 to 70% by weight based on the total weight of the particle; and (b) the base material, selected from hydrogenated plant oil, hydrogenated animal oil, C8-C64 saturated fatty acid or the derivatives thereof, and ranged from about 30 to 99.9% by weight based on the total weight of the particle. Also, the present invention discloses a method for producing the particle.

Abstract: A particle embedded with chemical substances, especially with physiological activity substances, is disclosed. The particle has (a) the embedded substances, embedded in base materials and ranged from about 0.1 to 70% by weight based on the total weight of the particle; and (b) the base material, selected from hydrogenated plant oil, hydrogenated animal oil, C8-C64 saturated fatty acid or the derivatives thereof, and ranged from about 30 to 99.9% by weight based on the total weight of the particle. Also, the present invention discloses a method for producing the particle.